Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79.4M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
27.6M
-
Shares change
-
-3.73M
-
Total reported value, excl. options
-
$684M
-
Value change
-
-$121M
-
Number of buys
-
49
-
Number of sells
-
-42
-
Price
-
$24.81
Significant Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q2 2021
119 filings reported holding AKRO - Akero Therapeutics, Inc. - COMMON STOCK as of Q2 2021.
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.6M shares
of 79.4M outstanding shares and own 34.75% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (3.49M shares), Redmile Group, LLC (2.8M shares), ALKEON CAPITAL MANAGEMENT LLC (2.49M shares), venBio Partners LLC (2.2M shares), BlackRock Inc. (1.85M shares), HHLR ADVISORS, LTD. (1.66M shares), WELLINGTON MANAGEMENT GROUP LLP (1.65M shares), Yiheng Capital Management, L.P. (1.5M shares), STATE STREET CORP (1.23M shares), and Point72 Asset Management, L.P. (1.19M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.